{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:26:33Z","timestamp":1791851193992,"version":"4.3.4"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00393-018-0481-y","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T03:59:43Z","timestamp":1530244783000},"page":"35-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten","S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs"],"prefix":"10.1007","volume":"77","author":[{"given":"C.","family":"Fiehn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Iking-Konert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Leipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Weseloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Frerix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Alten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baerwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Detert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gaubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gromnica-Ihle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-M.","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nothacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"N\u00fcsslein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Specker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wassenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wollenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"481_CR1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00393-015-0019-5","volume":"75","author":"K Albrecht","year":"2016","unstructured":"Albrecht K, Callhoff J, Edelmann E et\u00a0al (2016) Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA. Z\u00a0Rheumatol 75:90\u201396","journal-title":"Z Rheumatol"},{"key":"481_CR2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00393-016-0156-5","volume":"76","author":"K Albrecht","year":"2017","unstructured":"Albrecht K, Huscher D, Eidner T et\u00a0al (2017) Medical treatment of rheumatoid arthritis in 2014 : current data from the German collaborative arthritis centers. Z\u00a0Rheumatol 76:50\u201357","journal-title":"Z Rheumatol"},{"key":"481_CR3","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/annrheumdis-2015-208324","volume":"75","author":"D Aletaha","year":"2016","unstructured":"Aletaha D, Alasti F, Smolen JS (2016) Optimisation of a\u00a0treat-to-target approach in rheumatoid arthritis: strategies for the 3\u2011month time point. Ann Rheum Dis 75:1479\u20131485","journal-title":"Ann Rheum Dis"},{"key":"481_CR4","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC et\u00a0al (2007) Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56:3226\u20133235","journal-title":"Arthritis Rheum"},{"key":"481_CR5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et\u00a0al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"481_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-016-0927-z","volume":"18","author":"S Alivernini","year":"2016","unstructured":"Alivernini S, Peluso G, Fedele AL et al (2016) Tapering and discontinuation of TNF-alpha blockers without disease relapse using ultrasonography as a\u00a0tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther 18:39","journal-title":"Arthritis Res Ther"},{"key":"481_CR7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/1874312901206010303","volume":"6","author":"ML Andersson","year":"2012","unstructured":"Andersson ML, Bergman S, Soderlin MK (2012) The effect of stopping smoking on disease activity in rheumatoid arthritis (RA). Data from BARFOT, a\u00a0multicenter study of early RA. Open Rheumatol\u00a0J 6:303\u2013309","journal-title":"Open Rheumatol J"},{"key":"481_CR8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","volume":"63","author":"C Barnabe","year":"2011","unstructured":"Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:522\u2013529","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"481_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, Kastner P, Flaxenberg P et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a\u00a0six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73\u201381","journal-title":"Arthritis Rheum"},{"key":"481_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a\u00a0randomised phase 3 trial. Lancet 381:451\u2013460","journal-title":"Lancet"},{"key":"481_CR11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","volume":"74","author":"GR Burmester","year":"2015","unstructured":"Burmester GR, Kivitz AJ, Kupper H et\u00a0al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74:1037\u20131044","journal-title":"Ann Rheum Dis"},{"key":"481_CR12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R et al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a\u00a0randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840\u2013847","journal-title":"Ann Rheum Dis"},{"key":"481_CR13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Rigby WF, Van Vollenhoven RF et\u00a0al (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a\u00a0randomised controlled trial. Ann Rheum Dis 75:1081\u20131091","journal-title":"Ann Rheum Dis"},{"key":"481_CR14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.131252","volume":"41","author":"VP Bykerk","year":"2014","unstructured":"Bykerk VP, Lie E, Bartlett SJ et\u00a0al (2014) Establishing a\u00a0core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare workshop. J\u00a0Rheumatol 41:799\u2013809","journal-title":"J Rheumatol"},{"key":"481_CR15","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/annrheumdis-2016-210711","volume":"76","author":"K Chatzidionysiou","year":"2017","unstructured":"Chatzidionysiou K, Emamikia S, Nam J et al (2017) Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a\u00a0systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:1102\u20131107","journal-title":"Ann Rheum Dis"},{"key":"481_CR16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2017","unstructured":"Combe B, Landewe R, Daien CI et\u00a0al (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76:948\u2013959","journal-title":"Ann Rheum Dis"},{"key":"481_CR17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.21600","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, Luijtens K, Kavanaugh A (2012) Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12\u00a0weeks associated with low disease activity at 1 year. Arthritis Care Res (hoboken) 64:658\u2013667","journal-title":"Arthritis Care Res (hoboken)"},{"key":"481_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/acr.22218","volume":"66","author":"J Dale","year":"2014","unstructured":"Dale J, Purves D, Mcconnachie A et\u00a0al (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a\u00a0treat to target strategy. Arthritis Care Res (hoboken) 66:19\u201326","journal-title":"Arthritis Care Res (hoboken)"},{"key":"481_CR19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/annrheumdis-2013-204788","volume":"73","author":"PH Jong De","year":"2014","unstructured":"De Jong PH, Hazes JM, Han HK et al (2014) Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1\u2011year data of the tREACH trial. Ann Rheum Dis 73:1331\u20131339","journal-title":"Ann Rheum Dis"},{"key":"481_CR20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/annrheumdis-2012-202818","volume":"73","author":"D Uyl Den","year":"2014","unstructured":"Den Uyl D, Ter Wee M, Boers M et al (2014) A non-inferiority trial of an attenuated combination strategy (\u2018COBRA-light\u2019) compared to the original COBRA strategy: clinical results after 26\u00a0weeks. Ann Rheum Dis 73:1071\u20131078","journal-title":"Ann Rheum Dis"},{"key":"481_CR21","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/acr.22633","volume":"67","author":"M Dougados","year":"2015","unstructured":"Dougados M, Huizinga TW, Choy EH et al (2015) Evaluation of the disease activity score in twenty-eight joints-based flare definitions in rheumatoid arthritis: data from a\u00a0three-year clinical trial. Arthritis Care Res (hoboken) 67:1762\u20131766","journal-title":"Arthritis Care Res (hoboken)"},{"key":"481_CR22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Kissel K, Conaghan PG et al (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73:803\u2013809","journal-title":"Ann Rheum Dis"},{"key":"481_CR23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, Van Der Heijde D, Chen YC et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88\u201395","journal-title":"Ann Rheum Dis"},{"key":"481_CR24","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru N, Van Der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905\u20131913","journal-title":"Ann Rheum Dis"},{"key":"481_CR25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2015-209057","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Bingham CO 3rd, Burmester GR et al (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1\u2011year results from C\u2011EARLY, a\u00a0randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 76:96\u2013104","journal-title":"Ann Rheum Dis"},{"key":"481_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP et al (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24\u00a0months, with a\u00a012-month, double-blind treatment period. Ann Rheum Dis 74:19\u201326","journal-title":"Ann Rheum Dis"},{"key":"481_CR27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Gottenberg JE, Rubbert-Roth A et al (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a\u00a0single previous TNF inhibitor: SWITCH-RA, a\u00a0global, observational, comparative effectiveness study. Ann Rheum Dis 74:979\u2013984","journal-title":"Ann Rheum Dis"},{"key":"481_CR28","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, Fitzgerald O et\u00a0al (2014) Sustained remission with etanercept tapering in early rheumatoid arthritis. N\u00a0Engl J Med 371:1781\u20131792","journal-title":"N Engl J Med"},{"key":"481_CR29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"B Fautrel","year":"2016","unstructured":"Fautrel B, Pham T, Alfaiate T et al (2016) Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 75:59\u201367","journal-title":"Ann Rheum Dis"},{"key":"481_CR30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G et\u00a0al (2011) American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413","journal-title":"Ann Rheum Dis"},{"key":"481_CR31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s10067-013-2325-0","volume":"32","author":"C Fiehn","year":"2013","unstructured":"Fiehn C, Belke-Voss E, Krause D et al (2013) Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs. Clin Rheumatol 32:1735\u20131742","journal-title":"Clin Rheumatol"},{"key":"481_CR32","first-page":"A-1154","volume":"113","author":"C Fiehn","year":"2016","unstructured":"Fiehn C, Herzer P, Holle J et al (2016) Klug entscheiden in der Rheumatologie. Dtsch Arztebl 113:A-1154 (B-1939\/C-1953)","journal-title":"Dtsch. Arztebl."},{"key":"481_CR33","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/ard.2005.049338","volume":"65","author":"A Finckh","year":"2006","unstructured":"Finckh A, Choi HK, Wolfe F (2006) Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 65:1192\u20131197","journal-title":"Ann Rheum Dis"},{"key":"481_CR34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N\u00a0Engl J Med 367:495\u2013507","journal-title":"N Engl J Med"},{"key":"481_CR35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a\u00a0phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468","journal-title":"Lancet"},{"key":"481_CR36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, Van Der Heijde D et al (2017) Baricitinib, Methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506\u2013517","journal-title":"Arthritis Rheumatol"},{"key":"481_CR37","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C, Emery P, Van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a\u00a0randomised, double-blind, controlled phase 4 trial. Lancet 381:1541\u20131550","journal-title":"Lancet"},{"key":"481_CR38","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O et\u00a0al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N\u00a0Engl J Med 374:1243\u20131252","journal-title":"N Engl J Med"},{"key":"481_CR39","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"M Ghiti Moghadam","year":"2016","unstructured":"Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810\u20131817","journal-title":"Arthritis Rheumatol"},{"key":"481_CR40","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, Sorensen IJ, Loft AG et al (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1\u2011year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76:1426\u20131431","journal-title":"Ann Rheum Dis"},{"key":"481_CR41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","volume":"146","author":"YP Goekoop-Ruiterman","year":"2007","unstructured":"Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a\u00a0randomized trial. Ann Intern Med 146:406\u2013415","journal-title":"Ann Intern Med"},{"key":"481_CR42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.20452\/pamw.1131","volume":"122","author":"D Golicki","year":"2012","unstructured":"Golicki D, Newada M, Lis J et al (2012) Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 122:22\u201332","journal-title":"Pol Arch Med Wewn"},{"key":"481_CR43","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Brocq O, Perdriger A et al (2016) Non-TNF-targeted biologic vs a\u00a0second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a\u00a0first anti-TNF drug: a randomized clinical trial. JAMA 316:1172\u20131180","journal-title":"JAMA"},{"key":"481_CR44","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of Abatacept: results from the Pan-European Registry Analysis. Arthritis Rheumatol 68:1346\u20131352","journal-title":"Arthritis Rheumatol"},{"key":"481_CR45","unstructured":"Gremese E, Gigante MR, Tolusso B et\u00a0al (2015) Weight loss in obese rheumatoid arthritis (RA) patients improves disease activity without modifying RA treatment. Arthritis Rheumatol 67(Suppl 10). http:\/\/acrabstracts.org\/abstract\/weight-loss-in-obese-rheumatoid-arthritis-ra-patients-improves-disease-activity-without-modifying-ra-treatment\/ . Zugegriffen: 24.05.2018"},{"key":"481_CR46","doi-asserted-by":"crossref","first-page":"i4205","DOI":"10.1136\/bmj.i4205","volume":"354","author":"EA Haavardsholm","year":"2016","unstructured":"Haavardsholm EA, Aga AB, Olsen IC et\u00a0al (2016) Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 354:i4205","journal-title":"BMJ"},{"key":"481_CR47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","volume":"74","author":"LR Harrold","year":"2015","unstructured":"Harrold LR, Reed GW, Kremer JM et al (2015) The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 74:430\u2013436","journal-title":"Ann Rheum Dis"},{"key":"481_CR48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13075-016-1179-7","volume":"18","author":"LR Harrold","year":"2016","unstructured":"Harrold LR, Reed GW, Solomon DH et\u00a0al (2016) Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther 18:280","journal-title":"Arthritis Res Ther"},{"key":"481_CR49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ et\u00a0al (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 75:45\u201351","journal-title":"Ann Rheum Dis"},{"key":"481_CR50","doi-asserted-by":"crossref","first-page":"i1777","DOI":"10.1136\/bmj.i1777","volume":"353","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Barnabe C, Tomlinson G et al (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 353:i1777","journal-title":"BMJ"},{"key":"481_CR51","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","volume":"75","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Thorne JC, Pope JE et\u00a0al (2016) The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75:1003\u20131008","journal-title":"Ann Rheum Dis"},{"key":"481_CR52","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/annrheumdis-2013-203243","volume":"73","author":"L Heimans","year":"2014","unstructured":"Heimans L, Wevers-De Boer KV, Visser K et al (2014) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 73:1356\u20131361","journal-title":"Ann Rheum Dis"},{"key":"481_CR53","first-page":"S44","volume":"30","author":"ML Hetland","year":"2012","unstructured":"Hetland ML, Horslev-Petersen K (2012) The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a\u00a0treat-to-target strategy in early rheumatoid arhtritis. Clin Exp Rheumatol 30:S44\u201349","journal-title":"Clin Exp Rheumatol"},{"key":"481_CR54","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","volume":"66","author":"JN Hoes","year":"2007","unstructured":"Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560\u20131567","journal-title":"Ann Rheum Dis"},{"key":"481_CR55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2014-205752","volume":"74","author":"TW Huizinga","year":"2015","unstructured":"Huizinga TW, Conaghan PG, Martin-Mola E et al (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74:35\u201343","journal-title":"Ann Rheum Dis"},{"key":"481_CR56","first-page":"256","volume":"31","author":"D Huscher","year":"2013","unstructured":"Huscher D, Sengler C, Gromnica-Ihle E et al (2013) Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a\u00a0matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol 31:256\u2013262","journal-title":"Clin Exp Rheumatol"},{"key":"481_CR57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs JD, Cohen SB, Emery P et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a\u00a0meta-analysis. Ann Rheum Dis 72:329\u2013336","journal-title":"Ann Rheum Dis"},{"key":"481_CR58","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/acr.22303","volume":"66","author":"T Iwamoto","year":"2014","unstructured":"Iwamoto T, Ikeda K, Hosokawa J et al (2014) Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res (Hoboken) 66:1576\u20131581","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"481_CR59","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","volume":"75","author":"Y Kaneko","year":"2016","unstructured":"Kaneko Y, Atsumi T, Tanaka Y et al (2016) Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a\u00a0prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis 75:1917\u20131923","journal-title":"Ann Rheum Dis"},{"key":"481_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211937","author":"J Kay","year":"2017","unstructured":"Kay J, Schoels MM, Dorner T et al (2017) Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211937","journal-title":"Ann Rheum Dis"},{"key":"481_CR61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kev338","volume":"55","author":"EC Keystone","year":"2016","unstructured":"Keystone EC, Pope JE, Thorne JC et al (2016) Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology (Oxford) 55:327\u2013334","journal-title":"Rheumatology (Oxford)"},{"key":"481_CR62","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/keq406","volume":"50","author":"P Kiely","year":"2011","unstructured":"Kiely P, Walsh D, Williams R et\u00a0al (2011) Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity\u2014the early RA network (ERAN). Rheumatology (Oxford) 50:926\u2013931","journal-title":"Rheumatology (Oxford)"},{"key":"481_CR63","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","volume":"70","author":"NB Klarenbeek","year":"2011","unstructured":"Klarenbeek NB, Guler-Yuksel M, Van Der Kooij SM et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5\u2011year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039\u20131046","journal-title":"Ann Rheum Dis"},{"key":"481_CR64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a\u00a0randomized trial. Ann Intern Med 159:253\u2013261","journal-title":"Ann Intern Med"},{"key":"481_CR65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00393-012-1038-0","volume":"71","author":"K Kruger","year":"2012","unstructured":"Kruger K, Wollenhaupt J, Albrecht K et\u00a0al (2012) German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. Z\u00a0Rheumatol 71:592\u2013603","journal-title":"Z Rheumatol"},{"key":"481_CR66","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et\u00a0al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N\u00a0Engl J Med 370:2377\u20132386","journal-title":"N Engl J Med"},{"key":"481_CR67","doi-asserted-by":"crossref","first-page":"e3968","DOI":"10.1097\/MD.0000000000003968","volume":"95","author":"R Li","year":"2016","unstructured":"Li R, Zhao JX, Su Y et\u00a0al (2016) High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): a multicenter randomized clinical trial. Medicine (Baltimore) 95:e3968","journal-title":"Medicine (Baltimore)"},{"key":"481_CR68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53\u201361","journal-title":"Rheumatology (Oxford)"},{"key":"481_CR69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing J, Kekow J, Manger B et\u00a0al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Ann Rheum Dis 74:415\u2013421","journal-title":"Ann Rheum Dis"},{"key":"481_CR70","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/PPA.S133222","volume":"11","author":"JH Lofland","year":"2017","unstructured":"Lofland JH, Johnson PT, Ingham MP et al (2017) Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence 11:947\u2013958","journal-title":"Patient Prefer Adherence"},{"key":"481_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd000957.pub2","author":"MA Lopez-Olivo","year":"2014","unstructured":"Lopez-Olivo MA, Siddhanamatha HR, Shea B et al (2014) Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd000957.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"481_CR72","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13075-016-1194-8","volume":"18","author":"R Lupoli","year":"2016","unstructured":"Lupoli R, Pizzicato P, Scalera A et al (2016) Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a\u00a0systematic review and meta-analysis. Arthritis Res Ther 18:297","journal-title":"Arthritis Res Ther"},{"key":"481_CR73","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3899\/jrheum.151014","volume":"43","author":"SH Manders","year":"2016","unstructured":"Manders SH, Kievit W, Jansen TL et\u00a0al (2016) Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry. J\u00a0Rheumatol 43:1787\u20131794","journal-title":"J Rheumatol"},{"key":"481_CR74","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/acr.21913","volume":"65","author":"P Mandl","year":"2013","unstructured":"Mandl P, Balint PV, Brault Y et al (2013) Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a\u00a0multicenter, randomized study. Arthritis Care Res (hoboken) 65:879\u2013887","journal-title":"Arthritis Care Res (hoboken)"},{"key":"481_CR75","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","volume":"173","author":"JR Maneiro","year":"2013","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. Jama Intern Med 173:1416\u20131428","journal-title":"Jama Intern Med"},{"key":"481_CR76","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jbspin.2011.01.010","volume":"78","author":"G Mouterde","year":"2011","unstructured":"Mouterde G, Baillet A, Gaujoux-Viala C et al (2011) Optimizing methotrexate therapy in rheumatoid arthritis: a\u00a0systematic literature review. Joint Bone Spine 78:587\u2013592","journal-title":"Joint Bone Spine"},{"key":"481_CR77","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S et al (2017) Efficacy of biological disease-modifying antirheumatic drugs: a\u00a0systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:1113\u20131136","journal-title":"Ann Rheum Dis"},{"key":"481_CR78","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Villeneuve E, Hensor EM et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a\u00a0double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73:75\u201385","journal-title":"Ann Rheum Dis"},{"key":"481_CR79","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/rheumatology\/kev006","volume":"54","author":"E Naredo","year":"2015","unstructured":"Naredo E, Valor L, De La Torre I et al (2015) Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) 54:1408\u20131414","journal-title":"Rheumatology (Oxford)"},{"key":"481_CR80","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.3899\/jrheum.131299","volume":"41","author":"LM Ornbjerg","year":"2014","unstructured":"Ornbjerg LM, Ostergaard M, Boyesen P et\u00a0al (2014) Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. J\u00a0Rheumatol 41:2352\u20132360","journal-title":"J Rheumatol"},{"key":"481_CR81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pec.2016.07.019","volume":"100","author":"A Pasma","year":"2017","unstructured":"Pasma A, Hazes JM, Busschbach JJ et\u00a0al (2017) Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis. Patient Educ Couns 100:126\u2013132","journal-title":"Patient Educ Couns"},{"key":"481_CR82","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K et\u00a0al (2017) Safety of synthetic and biological DMARDs: a\u00a0systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 76:1101\u20131136","journal-title":"Ann Rheum Dis"},{"key":"481_CR83","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1136\/annrheumdis-2015-207900","volume":"75","author":"J Rech","year":"2016","unstructured":"Rech J, Hueber AJ, Finzel S et\u00a0al (2016) Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis 75:1637\u20131644","journal-title":"Ann Rheum Dis"},{"key":"481_CR84","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/annrheumdis-2011-200038","volume":"71","author":"H Rezaei","year":"2012","unstructured":"Rezaei H, Saevarsdottir S, Forslind K et al (2012) In early rheumatoid arthritis, patients with a\u00a0good initial response to methotrexate have excellent 2\u2011year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 71:186\u2013191","journal-title":"Ann Rheum Dis"},{"key":"481_CR85","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/annrheumdis-2013-204601","volume":"74","author":"S Saevarsdottir","year":"2015","unstructured":"Saevarsdottir S, Rezaei H, Geborek P et\u00a0al (2015) Current smoking status is a\u00a0strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 74:1509\u20131514","journal-title":"Ann Rheum Dis"},{"key":"481_CR86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.27758","volume":"63","author":"S Saevarsdottir","year":"2011","unstructured":"Saevarsdottir S, Wedren S, Seddighzadeh M et\u00a0al (2011) Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 63:26\u201336","journal-title":"Arthritis Rheum"},{"key":"481_CR87","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, Jaffe JS, Freundlich B (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u2265 15\u202fmg may be overcome with subcutaneous administration. Ann Rheum Dis 73:1549\u20131551","journal-title":"Ann Rheum Dis"},{"key":"481_CR88","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.115.002867","author":"TS Sharma","year":"2016","unstructured":"Sharma TS, Wasko MC, Tang X et\u00a0al (2016) Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J\u00a0Am Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.115.002867","journal-title":"J Am Heart Assoc"},{"key":"481_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd000951.pub2","author":"B Shea","year":"2013","unstructured":"Shea B, Swinden MV, Tanjong Ghogomu E et\u00a0al (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd000951.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"481_CR90","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr. et\u00a0al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"481_CR91","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","volume":"11","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Aletaha D (2015) Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 11:276\u2013289","journal-title":"Nat Rev Rheumatol"},{"key":"481_CR92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR et\u00a0al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3\u201315","journal-title":"Ann Rheum Dis"},{"key":"481_CR93","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Burmester GR, Combe B et al (2016) Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2\u2011year efficacy and safety results from the randomised EXXELERATE study. Lancet 388:2763\u20132774","journal-title":"Lancet"},{"key":"481_CR94","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2008.090019","volume":"68","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Han C, Van Der Heijde DM et\u00a0al (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 68:823\u2013827","journal-title":"Ann Rheum Dis"},{"key":"481_CR95","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","volume":"353","author":"JS Smolen","year":"1999","unstructured":"Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a\u00a0double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259\u2013266","journal-title":"Lancet"},{"key":"481_CR96","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a\u00a0multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210\u2013221","journal-title":"Lancet"},{"key":"481_CR97","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"481_CR98","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P et\u00a0al (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a\u00a0randomised controlled trial. Lancet 381:918\u2013929","journal-title":"Lancet"},{"key":"481_CR99","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Van Der Heijde DM, Clair StEW et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702\u2013710","journal-title":"Arthritis Rheum"},{"key":"481_CR100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-015-0671-9","volume":"17","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Wollenhaupt J, Gomez-Reino JJ et al (2015) Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to gauge remission and joint damage progression in methotrexate (MTX)-naive patients with early erosive rheumatoid arthritis (AGREE). Arthritis Res Ther 17:157","journal-title":"Arthritis Res Ther"},{"key":"481_CR101","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R et al (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2\u2011year results from the AMPLE trial. Ann Rheum Dis 75:709\u2013714","journal-title":"Ann Rheum Dis"},{"key":"481_CR102","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/acr.22629","volume":"67","author":"JA Sparks","year":"2015","unstructured":"Sparks JA, Halperin F, Karlson JC et\u00a0al (2015) Impact of bariatric surgery on patients with rheumatoid arthritis. Arthritis Care Res (hoboken) 67:1619\u20131626","journal-title":"Arthritis Care Res (hoboken)"},{"key":"481_CR103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer MA, Schoels MM, Smolen JS et\u00a0al (2016) Evidence for treating rheumatoid arthritis to target: results of a\u00a0systematic literature search update. Ann Rheum Dis 75:16\u201322","journal-title":"Ann Rheum Dis"},{"key":"481_CR104","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/annrheumdis-2013-203743","volume":"73","author":"MA Stoffer","year":"2014","unstructured":"Stoffer MA, Smolen JS, Woolf A et al (2014) Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis 73:902\u2013905","journal-title":"Ann Rheum Dis"},{"key":"481_CR105","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914\u20131920","journal-title":"Ann Rheum Dis"},{"key":"481_CR106","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JW, De Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952\u2013957","journal-title":"Ann Rheum Dis"},{"key":"481_CR107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","volume":"74","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Hirata S, Kubo S et al (2015) Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1\u2011year outcome of the HONOR study. Ann Rheum Dis 74:389\u2013395","journal-title":"Ann Rheum Dis"},{"key":"481_CR108","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, Van Der Heijde D et\u00a0al (2017) Baricitinib versus placebo or Adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"key":"481_CR109","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/ard.2011.154583","volume":"71","author":"MM Ter Wee","year":"2012","unstructured":"Ter Wee MM, Lems WF, Usan H et\u00a0al (2012) The effect of biological agents on work participation in rheumatoid arthritis patients: a\u00a0systematic review. Ann Rheum Dis 71:161\u2013171","journal-title":"Ann Rheum Dis"},{"key":"481_CR110","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2012-202967","volume":"73","author":"J Aken Van","year":"2014","unstructured":"Van Aken J, Heimans L, Gillet-Van Dongen H et al (2014) Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis 73:396\u2013400","journal-title":"Ann Rheum Dis"},{"key":"481_CR111","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","volume":"74","author":"D Der Heijde Van","year":"2015","unstructured":"Van Der Heijde D, Aletaha D, Carmona L et al (2015) 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 74:8\u201313","journal-title":"Ann Rheum Dis"},{"key":"481_CR112","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.111171","volume":"39","author":"D Der Heijde Van","year":"2012","unstructured":"Van Der Heijde D, Keystone EC, Curtis JR et al (2012) Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a\u00a0post-hoc analysis of the RAPID 1 trial. J\u00a0Rheumatol 39:1326\u20131333","journal-title":"J Rheumatol"},{"key":"481_CR113","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D Der Heijde Van","year":"2013","unstructured":"Van Der Heijde D, Tanaka Y, Fleischmann R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a\u00a0twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559\u2013570","journal-title":"Arthritis Rheum"},{"key":"481_CR114","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","volume":"31","author":"DM Der Heijde Van","year":"1992","unstructured":"Van Der Heijde DM, Van Riel PL, Van Leeuwen MA et al (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 31:519\u2013525","journal-title":"Br J Rheumatol"},{"key":"481_CR115","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","volume":"71","author":"A Der Maas Van","year":"2012","unstructured":"Van Der Maas A, Kievit W, Van Den Bemt BJ et al (2012) Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 71:1849\u20131854","journal-title":"Ann Rheum Dis"},{"key":"481_CR116","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","volume":"56","author":"H Dongen Van","year":"2007","unstructured":"Van Dongen H, Van Aken J, Lard LR et al (2007) Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a\u00a0double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424\u20131432","journal-title":"Arthritis Rheum"},{"key":"481_CR117","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel Van","year":"1996","unstructured":"Van Gestel AM, Prevoo ML, Van \u2019T Hof MA et\u00a0al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum 39:34\u201340","journal-title":"Arthritis Rheum"},{"key":"481_CR118","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","volume":"350","author":"N Herwaarden Van","year":"2015","unstructured":"Van Herwaarden N, Van Der Maas A, Minten MJ et al (2015) Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 350:h1389","journal-title":"BMJ"},{"key":"481_CR119","first-page":"20","volume":"24","author":"MA Leeuwen Van","year":"1997","unstructured":"Van Leeuwen MA, Van Rijswijk MH, Sluiter WJ et\u00a0al (1997) Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a\u00a0decision support system. J\u00a0Rheumatol 24:20\u201327","journal-title":"J Rheumatol"},{"key":"481_CR120","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven Van","year":"2012","unstructured":"Van Vollenhoven RF, Fleischmann R, Cohen S et\u00a0al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N\u00a0Engl J Med 367:508\u2013519","journal-title":"N Engl J Med"},{"key":"481_CR121","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","volume":"75","author":"RF Vollenhoven Van","year":"2016","unstructured":"Van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M et al (2016) Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 75:52\u201358","journal-title":"Ann Rheum Dis"},{"key":"481_CR122","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","volume":"76","author":"P Verschueren","year":"2017","unstructured":"Verschueren P, De Cock D, Corluy L et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a\u00a0treat-to-target approach: 1\u2011year results of CareRA, a\u00a0randomised pragmatic open-label superiority trial. Ann Rheum Dis 76:511\u2013520","journal-title":"Ann Rheum Dis"},{"key":"481_CR123","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","volume":"74","author":"P Verschueren","year":"2015","unstructured":"Verschueren P, De Cock D, Corluy L et al (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16\u00a0weeks of treatment: the CareRA trial. Ann Rheum Dis 74:27\u201334","journal-title":"Ann Rheum Dis"},{"key":"481_CR124","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","volume":"68","author":"K Visser","year":"2009","unstructured":"Visser K, Van Der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a\u00a0systematic review of the literature. Ann Rheum Dis 68:1094\u20131099","journal-title":"Ann Rheum Dis"},{"key":"481_CR125","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","volume":"74","author":"EM Vital","year":"2015","unstructured":"Vital EM, Dass S, Buch MH et\u00a0al (2015) An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a\u00a0randomised controlled trial. Ann Rheum Dis 74:1195\u20131201","journal-title":"Ann Rheum Dis"},{"key":"481_CR126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21710","volume":"21","author":"A Wailoo","year":"2017","unstructured":"Wailoo A, Hock ES, Stevenson M et al (2017) The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a\u00a0systematic review and cost-effectiveness analysis. Health Technol Assess 21:1\u2013258","journal-title":"Health Technol Assess"},{"key":"481_CR127","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13075-015-0841-9","volume":"17","author":"ME Weinblatt","year":"2015","unstructured":"Weinblatt ME, Fleischmann R, Van Vollenhoven RF et al (2015) Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a\u00a0diverse rheumatoid arthritis population. Arthritis Res Ther 17:325","journal-title":"Arthritis Res Ther"},{"key":"481_CR128","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/ard.2009.122101","volume":"69","author":"S Ziegler","year":"2010","unstructured":"Ziegler S, Huscher D, Karberg K et\u00a0al (2010) Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997\u20132007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 69:1803\u20131808","journal-title":"Ann Rheum Dis"},{"key":"481_CR129","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/annrheumdis-2013-203341","volume":"73","author":"A Zink","year":"2014","unstructured":"Zink A, Manger B, Kaufmann J et\u00a0al (2014) Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis 73:1673\u20131676","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0481-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0481-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:19:52Z","timestamp":1751703592000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0481-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":129,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0481-y","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"3 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Angaben zum Interessenskonflikt aller Leitlinienautoren sind im\n                      Leitlinienreport\n                      unter\n                      \n                      einsehbar.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}